Skip to main content
. 2022 Feb 3;11(2):205. doi: 10.3390/pathogens11020205

Table 2.

Comparisons between cerebral cryptococcomas caused by C. neoformans and C. gattii.

C. neoformans C. gattii
Prevalence * 74% 26%
Clinical manifestations

  • Headache

 56% 50%

  • Altered mental status or confusion

 52% 25%

  • Visual disturbances

 16% 13%

  • Seizures

 16% 0%

  • Fever

 20% 25%

  • Chills

 0% 13%

  • Fatigue

 16% 25%

  • Weight loss

 4% 13%

  • Papilledema

 20% 25%

  • Upper extremity weakness

 20% 13%

  • Time from symptom onset to presentation (days), median (range)

 30 (3–365) 29 (3–270)
Radiographic findings

  • One or more lesions throughout the brain parenchyma

 40% 56%

  • Perilesional edema

 77% 47%

  • Hydrocephalus

 71% 33%
Treatment regimens

  • Amphotericin B-based formulation

 88% 100%

  • Amphotericin B-based formulation in combination with flucytosine or fluconazole

 57% 89%

  • “Induction” therapy duration among survivors (days), median (range)

 42 (10–60) 38 (7–84)

  • “Maintenance” therapy duration among survivors (days), median (range)

 126 (60–730) 317.5 (12–365)
Follow-up, median (range) 302.5 (30–4380) 279 (7–1460)

*, based on the 34 cases in which an organism was isolated and speciated [19,22,23,24,26,27,28,29,30,32,34,36,37,39,41,44,45,46,47,50,52,53,54].